Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2016-04-25 Earnings Release
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document explicitly announces the consolidated revenue for the first quarter of 2016 ("Chiffre d'affaires du 1er trimestre 2016"). It provides key financial highlights, comparative figures, and management commentary related to this short period. This structure aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, rather than a comprehensive Interim/Quarterly Report (IR) or a full Annual Report (10-K). The document is short and focused on the period's results announcement. Q1 2016
2016-04-25 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 6, 2016, announcing the launch of a new diagnostic instrument (BioCLIA® 1 200) and acceleration of the company's *in vitro* Diagnostic Business Unit. It details product features, partnership updates (with HOB Biotech), and includes quotes from the CEO. This type of announcement, focusing on a new product launch, strategic development, or significant operational news, is typically classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Capital/Financing Update (CAP). Since it is not a formal financial report (10-K, IR, MRQ) nor a management discussion (MDA), and it is an announcement of a business event, RNS is the most appropriate general regulatory category, although it shares characteristics with an Investor Presentation (IP) or a general corporate update. Given the options, RNS serves as the best fit for a broad corporate announcement not covered by the specific financial or governance codes.
2016-04-06 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated April 6, 2016, announcing the launch of a new automated diagnostics system (BioCLIA® 1 200) and updates on the company's *In Vitro* Diagnostics business unit. It details product development, partnerships (with HOB Biotech), and includes quotes from the CEO. This content is characteristic of a general business update or news release, not a formal regulatory filing like a 10-K, an Earnings Release (ER) focused purely on financial figures, or a specific shareholder document. Since it is a general announcement that doesn't fit the highly specific categories (like DIV, DIRS, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which often captures general corporate news releases that are filed with regulators but don't match other specific types.
2016-04-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references the French Commercial Code and AMF regulations, and presents a table showing the total number of shares and voting rights as of March 31, 2016. This type of mandatory disclosure regarding the capital structure and voting rights directly relates to changes in the company's share count or capital structure. While it is a specific regulatory disclosure, it most closely aligns with announcements concerning capital changes or share structure. The closest fit among the provided codes is 'Share Issue/Capital Change' (SHA), as it details the current total share count which underpins the capital structure. It is not a general earnings release (ER), an interim report (IR), or a director's dealing (DIRS). Given the specific nature of reporting total shares and voting rights, SHA is the most appropriate classification.
2016-04-04 French
Communicated under the obligation to provide permanent information / Other communications
Audit Report / Information Classification · 95% confidence The document is dated March 22, 2016, and announces that Theradiag is presenting results obtained with its Lisa Tracker® tests at the European Crohn's and Colitis Organisation (ECCO) Congress held between March 16 and March 19, 2016. The text details scientific findings, mentions specific abstracts, and includes quotes from management regarding the scientific interest in biotherapy monitoring. This format—a press release announcing participation and key findings at a scientific conference—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a formal regulatory filing (like 10-K or IR) but rather an announcement of business/scientific developments, and it is not explicitly a transcript (CT) or a presentation (IP), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS) if it's purely informational. Given the structure, it reads like a press release highlighting recent business/scientific achievements, which often overlaps with the function of an ER or a general announcement. However, since it is not reporting quarterly financial results directly but rather scientific conference participation, and it is not a short notice about a report being available (ruling out RPA), the most appropriate category for a company press release detailing scientific progress and market positioning is often the general Regulatory Filings (RNS) category, or potentially ER if it's part of a regular cycle. Given the content focuses heavily on scientific validation and market positioning rather than core financial performance metrics typical of an ER, RNS is a safer general classification for non-standard announcements. Upon review, this is a standard press release announcing scientific data presented at a conference. This type of announcement, which is not a formal financial report (10-K, IR, ER) or a specific corporate action (DIV, CAP), falls under the general Regulatory Filings (RNS) category as a miscellaneous announcement. Q1 2016
2016-03-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 15, 2016, announcing that Theradiag will present preliminary results regarding a microRNA signature predictive of treatment response in locally advanced rectal cancers at the JFHOD congress. It details scientific findings, quotes executives and researchers, and provides background information on the disease and the involved institutions (Theradiag and ICM). This format—a formal announcement of scientific/business progress, often released to the public and investors—is characteristic of a general press release or news item. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), an earnings release (ER), or a specific shareholder communication (DEF 14A, DVA), the most appropriate classification among the provided options for a general corporate/scientific update that isn't a formal financial report or a specific transaction announcement is the general Regulatory Filings/Announcements category, RNS, as it serves as a broad communication channel for non-standardized news. It is not an Investor Presentation (IP) as it is a text-based press release, not a slide deck, nor is it a Call Transcript (CT). Given the context of financial reporting databases, RNS is often used for press releases that convey material, non-standardized information.
2016-03-15 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.